SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 77.69 |
| Enterprise Value ($M) | 52.47 |
| Book Value ($M) | 22.00 |
| Book Value / Share | 0.60 |
| Price / Book | 3.53 |
| NCAV ($M) | 21.68 |
| NCAV / Share | 0.59 |
| Price / NCAV | 3.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.87 |
| Return on Assets (ROA) | -0.71 |
| Return on Equity (ROE) | -1.66 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.84 |
| Current Ratio | 2.84 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 52.13 |
| Assets | 52.45 |
| Liabilities | 30.45 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 4.96 | -3.18 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 85,970 | 334,476 | 25.70 | |
| 98,340 | 244,082 | 40.29 | |
| 96,199 | 303,114 | 31.74 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| OTLK – Outlook Therapeutics, Inc. | PALI – Palisade Bio, Inc. |
| PCSA – Processa Pharmaceuticals, Inc. | PHIO – Phio Pharmaceuticals Corp. |
| PIRS – Pieris Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io